Table of contents
September 2002 Vol 2 No 9
In this issue
p635 | doi:10.1038/nrc901
Research Highlights
Genomic instability: Chromosome crisis
p638 | doi:10.1038/nrc888
Tumorigenesis: Hang on tight!
p638 | doi:10.1038/nrc890
Tumour progression: Destroy the environment!
p638 | doi:10.1038/nrc891
Immunology: Presentation is everything
p638 | doi:10.1038/nrc893
In the news
Collaborative effort
p638 | doi:10.1038/nrc896
News in Brief
Glioblastoma | Cell Migration | Epidemiology | Therapeutics
p639 | doi:10.1038/nrc895
Therapeutics: Stop signals
p640 | doi:10.1038/nrc892
Genetics: Bridging the divide
p641 | doi:10.1038/nrc897
Trial Watch
Targeting leukaemia | Efficacy of imatinib
p641 | doi:10.1038/nrc898
Oncogenes: One small step for mankind...
p642 | doi:10.1038/nrc889
Tumour immunity: Plugging the gap
p642 | doi:10.1038/nrc902
Angiogenesis: Endostatin and Wnt signalling
p643 | doi:10.1038/nrc894
News and Analysis
From the analyst's couch
Selective anticancer drugs
p645 | doi:10.1038/nrc900
Reviews
The Bcl2 family: regulators of the cellular life-or-death switch
Suzanne Cory & Jerry M. Adams
p647 | doi:10.1038/nrc883
Strategies for MMP inhibition in cancer: innovations for the post-trial era
Christopher Mark Overall & Carlos López-Otín
p657 | doi:10.1038/nrc884
Molecular basis of the VHL hereditary cancer syndrome
William G. Kaelin, Jr
p673 | doi:10.1038/nrc885
Molecular imaging of cancer with positron emission tomography
Sanjiv Sam Gambhir
p683 | doi:10.1038/nrc882
Are vitamin and mineral deficiencies a major cancer risk?
Bruce N. Ames & Patricia Wakimoto
p694 | doi:10.1038/nrc886
Perspective
Timeline
How acute promyelocytic leukaemia revived arsenic
Jun Zhu, Zhu Chen, Valérie Lallemand-Breitenbach & Hugues de Thé
p705 | doi:10.1038/nrc887

